PROTAC Scale-Up Manufacturing Services for R&D

Name: PROTAC Scale-Up Production
Brand: BOC Sciences

Advancing a PROTAC from early discovery synthesis to reliable scale-up production is rarely a simple increase in reaction volume. PROTAC molecules often contain multiple functional domains, high molecular weight structures, flexible linkers, stereochemical complexity, and challenging physicochemical profiles, all of which can affect reaction conversion, impurity formation, isolation, solubility, and batch consistency. For pharmaceutical researchers, medicinal chemists, and drug development teams, the key question is not only whether a PROTAC can be synthesized, but whether it can be produced reproducibly at the scale required for downstream research and development studies.

BOC Sciences provides integrated PROTAC scale-up production services covering route assessment, intermediate preparation, process optimization, purification development, analytical characterization, and batch production. Building on our expertise in PROTAC design services, linker chemistry, E3 ligase ligand synthesis, and targeted protein degradation research support, we help clients bridge the gap between milligram-level discovery compounds and gram-to-hundred-gram research material supply.

Request a Consultation Explore Services

Services

BOC Sciences PROTAC Scale-Up Production Capabilities

Synthetic Route Assessment and Redesign We evaluate discovery-stage synthetic routes for scalability, operational robustness, raw material accessibility, protecting group strategy, reaction selectivity, and purification burden. When the original route is not suitable for scale-up, our chemists redesign key steps to reduce synthetic risk, improve intermediate stability, and simplify downstream isolation.
Key Intermediate and Building Block Production BOC Sciences supports the preparation of target protein ligands, E3 ligase ligands, linker-functionalized intermediates, and bifunctional building blocks. Our team can also assist with linker design and optimization services when linker length, polarity, rigidity, or reactive handles affect process performance.
Process Optimization for Scale-Up We optimize reaction parameters including solvent system, reagent stoichiometry, addition sequence, concentration, temperature profile, reaction time, work-up procedure, and crystallization or precipitation conditions. The goal is to establish a practical process that maintains conversion, minimizes side reactions, and supports reproducible batch production.
Multi-Gram to Hundred-Gram Production Our scale-up production services support PROTAC research programs requiring larger quantities of lead compounds, analog series, advanced intermediates, and reference materials. We design stepwise scale-up plans to reduce technical uncertainty and generate materials suitable for biological evaluation, formulation exploration, and mechanism-focused studies.
Purification and Isolation Development PROTACs may show broad chromatographic peaks, strong adsorption, aggregation tendency, or poor crystallinity. BOC Sciences develops practical purification strategies using preparative chromatography, reverse-phase systems, normal-phase separation, precipitation, recrystallization screening, salt-form exploration, and solvent exchange to improve recovery and batch quality.
Analytical Characterization and Batch Documentation We provide analytical support for identity confirmation, purity assessment, impurity tracking, residual solvent evaluation, water content, stability observation, and batch-to-batch comparison. Analytical data can be aligned with downstream needs such as PROTAC in vitro evaluation and activity profiling.

Need Reliable Scale-Up for Complex PROTAC Molecules?

From route optimization to purified batch production, BOC Sciences helps convert discovery-stage PROTACs into reproducible research material supply.

Get a Quote

Platforms

Technical Platforms Supporting PROTAC Scale-Up Production

Route Scouting and Parallel Condition Screening We use route scouting and parallel reaction screening to identify more scalable transformations and reduce late-stage failure risks. Solvent, base, catalyst, and coupling reagent screening Reaction concentration and temperature optimization Work-up simplification and impurity reduction
PROTAC Linker and Conjugation Chemistry Platform Our chemistry platform supports PEG, alkyl, rigid, cleavable, and functionalized linker systems for diverse PROTAC architectures. Amide coupling, click chemistry, and nucleophilic substitution Late-stage linker installation and modular assembly Hydrophilicity and steric effect adjustment
Preparative Purification Platform We develop purification methods suitable for high molecular weight and polarity-diverse PROTAC molecules. Preparative HPLC and flash chromatography Reverse-phase and normal-phase method development Precipitation, trituration, and recrystallization screening
Analytical Method Development Robust analytical methods are developed to monitor reaction progress, impurity trends, and final batch consistency. HPLC, LC-MS, HRMS, and NMR characterization Impurity profile comparison across scale-up batches Stability-indicating observation under selected conditions
Solubility and Stability Optimization For PROTACs with poor solubility or handling difficulty, we explore practical approaches to improve processability and material usability. Salt, co-solvent, and solvent-exchange evaluation Solid-state handling and storage condition exploration Support for solubility and stability assessment
Integrated Scale-Up Project Management Our chemists, analytical scientists, and project managers coordinate each stage to support efficient decision-making and transparent progress tracking. Stepwise risk assessment and scale-up planning Regular data review and route adjustment Final batch summary and technical recommendations

Importance

Why Expertise Matters in PROTAC Scale-Up Production?

Complex Molecular Architecture

PROTACs integrate a target ligand, E3 ligase ligand, and linker in one molecule. This complexity can create multiple reactive sites, solubility limits, conformational flexibility, and difficult impurity patterns during scale-up.

Route-Dependent Scalability

A route that works at milligram scale may become inefficient at gram scale due to long reaction times, low concentration, unstable intermediates, expensive reagents, or chromatography-heavy purification.

Purification Bottlenecks

PROTACs can be difficult to isolate because related impurities may have similar polarity and retention behavior. Efficient purification development is essential for usable material recovery.

Batch Consistency Requirements

Downstream biological assays require consistent materials. BOC Sciences focuses on reaction reproducibility, impurity control, and analytical comparability across scale-up batches.

Workflow

Our PROTAC Scale-Up Production Workflow

01

Project Evaluation and Target Definition

We review the target structure, existing route, available analytical data, desired scale, purity expectations, timeline priorities, and downstream research use to define a practical scale-up strategy.

02

Route Feasibility and Risk Mapping

Our team identifies high-risk steps, unstable intermediates, low-yield transformations, difficult isolations, and cost-driving materials before recommending route optimization or redesign.

03

Small-Scale Process Verification

Key reactions are reproduced at controlled scale to confirm conversion, impurity profile, isolation behavior, and analytical detectability before larger-scale execution.

04

Reaction and Work-Up Optimization

We optimize parameters such as stoichiometry, solvent, temperature, reaction concentration, addition order, quench conditions, extraction, washing, and solvent exchange.

05

Purification Method Development

Chromatographic and non-chromatographic purification methods are compared to improve recovery, remove structurally related impurities, and reduce the purification burden at larger scale.

06

Stepwise Scale-Up Production

The optimized process is scaled progressively, typically from milligram to gram and then to multi-gram or hundred-gram batches, depending on project requirements and process behavior.

07

Final Characterization and Data Review

Final batches are analyzed by appropriate methods such as HPLC, LC-MS, HRMS, NMR, and water content or residual solvent testing when needed for research use.

08

Technical Summary and Next-Step Support

We provide a clear summary of route performance, batch results, impurity observations, and recommendations for future production or additional optimization.

Move Your PROTAC Candidate Beyond Discovery Scale

Partner with BOC Sciences to develop a scalable, reproducible, and research-ready production strategy for complex PROTAC molecules.

Talk to Experts

Our Advantages

BOC Sciences Advantages in PROTAC Scale-Up Production

Deep PROTAC Chemistry Experience

Our teams understand the synthetic behavior of bifunctional degraders, E3 ligase ligands, linkers, and target-binding motifs across diverse PROTAC programs.

Integrated Chemistry and Analytics

Process chemists and analytical scientists work together from the beginning, enabling faster troubleshooting of conversion, impurity, and purification issues.

Flexible Scale and Service Scope

We support single-step intermediate preparation, full-route production, route rescue, impurity investigation, and repeated batch production based on project needs.

Problem-Solving Purification Strategy

For difficult PROTAC separations, we compare chromatographic, precipitation, recrystallization, and solvent-based strategies to balance recovery and material quality.

Structure-Aware Optimization

Our optimization considers linker composition, ligand polarity, stereochemical sensitivity, functional group compatibility, and possible degradation pathways.

Downstream Research Alignment

Scale-up production can be coordinated with PROTAC activity assay support to help clients connect material quality with functional performance.

Applications

Applications of PROTAC Scale-Up Production

Lead Compound Supply

Produce sufficient quantities of optimized PROTAC leads for repeat biological testing, mechanistic studies, selectivity evaluation, and formulation exploration.

Analog and SAR Expansion

Prepare focused PROTAC analog sets to evaluate linker length, ligand orientation, E3 ligase recruitment, polarity adjustment, and degradation potency relationships.

Mechanism-of-Action Research

Supply research materials for target engagement, ternary complex formation, ubiquitination, proteasome dependency, and degradation pathway studies.

Comparative E3 Ligase Strategy

Scale up CRBN-, VHL-, IAP-, or MDM2-based degrader candidates to compare degradation efficiency, selectivity, and cellular response across E3 ligase systems.

Solubility and Formulation Exploration

Generate larger batches for salt screening, co-solvent studies, solid dispersion exploration, or other material handling investigations related to PROTAC processability.

Targeted Protein Degradation Programs

Support oncology, immunology, neurodegeneration, and other disease-relevant discovery programs that require reproducible PROTAC material production for research studies.

Case Study

Client Success Stories: PROTAC Scale-Up Production

Project Background

A US-based biotechnology company was developing an androgen receptor (AR)-targeting PROTAC for hormone-driven oncology research. The molecule consisted of a hydrophobic AR ligand, a CRBN-recruiting ligand, and a medium-length PEG-alkyl hybrid linker designed to balance cellular permeability and target degradation potency. Although the discovery route delivered milligram-scale material for early in vitro screening, the client required multi-gram quantities for repeated degradation assays, selectivity profiling, and formulation feasibility studies.

Technical Challenges

The original synthesis showed unstable yield during late-stage linker coupling, significant formation of a deprotected linker-related impurity, and poor recovery during final purification. The final PROTAC also showed strong adsorption on silica gel and broad peaks under several chromatographic conditions, making the discovery purification method unsuitable for scale-up production.

BOC Sciences Solutions

Route Reorganization: We compared four assembly sequences and selected a route in which the AR ligand-linker intermediate was prepared first, followed by final coupling with the CRBN ligand. This reduced exposure of the sensitive linker motif to repeated acidic and basic conditions.
Coupling Condition Optimization: Twelve coupling conditions were evaluated by adjusting reagent type, base strength, solvent polarity, reaction concentration, and addition order. The selected condition improved conversion while reducing the linker-derived side product.
Purification Strategy Development: We screened reverse-phase preparative HPLC, normal-phase chromatography, precipitation-assisted clean-up, and solvent washing. A two-step purification workflow was selected to remove early-eluting impurities before final polishing.

Project Outcomes

BOC Sciences explored 16 route and process variables and delivered 9.8 g of the AR-targeting PROTAC over two comparable batches. The optimized process increased final-step isolated yield from 24% to 61%, reduced the major linker-related impurity, and improved material handling during solvent exchange. The client obtained sufficient material for expanded in vitro degradation studies, AR pathway analysis, and formulation exploration.

Project Background

A European pharmaceutical research team was developing a VHL-recruiting PROTAC against a disease-relevant kinase target. The molecule contained a chiral hydroxyproline-derived VHL ligand, a hydrophobic kinase ligand, and a semi-rigid linker. Early synthesis was successful at milligram scale, but the client experienced batch-to-batch variability during gram-scale attempts.

Technical Challenges

Major issues included incomplete linker installation, epimerization risk near the VHL ligand motif, strong adsorption during chromatography, and formation of a closely eluting oxidized impurity. These issues reduced final recovery and complicated analytical release for research use.

BOC Sciences Solutions

Stepwise Condition Screening: We evaluated base strength, solvent polarity, temperature, and reagent addition sequence to reduce epimerization and improve linker conversion.
Impurity Tracking: LC-MS and NMR were used to identify the oxidized impurity, after which the work-up and solvent-exposure window were redesigned to reduce its formation.
Isolation Optimization: We replaced a chromatography-heavy intermediate isolation with precipitation and solvent washing, then reserved preparative chromatography for final purification only.

Project Outcomes

BOC Sciences explored 24 process conditions and selected a controlled low-temperature coupling strategy with shortened post-reaction handling. The optimized process produced 38 g of the VHL-based kinase PROTAC over two comparable batches. Compared with the client's original process, the selected approach improved reproducibility, reduced the oxidized impurity level, and provided material suitable for extended in vitro degradation and selectivity studies.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

Why is PROTAC scale-up production challenging?

PROTAC scale-up production is challenging because most PROTAC molecules have complex bifunctional architectures, high molecular weights, multiple synthetic fragments, and strong dependence on linker chemistry. During scale-up, issues such as incomplete coupling, poor solubility, impurity accumulation, difficult purification, and batch-to-batch variation may become more obvious than in milligram-scale synthesis. BOC Sciences helps clients evaluate synthetic routes, optimize reaction parameters, control key intermediates, and establish reliable analytical methods so that PROTAC candidates can be produced more consistently for drug discovery and preclinical research programs.

How is a PROTAC synthesis route optimized?

A PROTAC synthesis route is optimized by carefully assessing the target protein ligand, E3 ligase ligand, linker structure, coupling sequence, protecting group strategy, and purification burden. For many PROTAC projects, the order of fragment assembly can strongly affect yield, impurity formation, and scalability. BOC Sciences evaluates multiple synthetic routes and reaction conditions, including solvent systems, coupling reagents, temperature profiles, and intermediate handling methods. This route-development approach helps identify a more practical and reproducible process for producing PROTAC compounds from early discovery scale to larger research-scale batches.

How are PROTAC impurities controlled during scale-up?

PROTAC impurities are controlled through early impurity-risk assessment, reaction monitoring, intermediate quality control, and purification strategy optimization. Common impurity sources include unreacted ligands, linker-related byproducts, over-coupled species, degradation products, stereochemical impurities, and difficult-to-remove hydrophobic components. BOC Sciences uses analytical tools such as HPLC, LC-MS, HRMS, and NMR to track impurity profiles across key synthetic steps. By adjusting reaction endpoints, reagent equivalents, workup conditions, and preparative purification methods, we help reduce impurity formation and improve consistency in PROTAC scale-up production.

How are hydrophobic PROTACs scaled up?

Hydrophobic PROTACs are scaled up by addressing solubility, reaction homogeneity, aggregation tendency, and purification recovery at an early stage. Highly hydrophobic PROTAC molecules may dissolve poorly, react unevenly, or show low recovery during isolation and preparative purification. BOC Sciences supports hydrophobic PROTAC scale-up by screening suitable solvent systems, adjusting reaction concentration, optimizing addition sequence, and evaluating linker or intermediate strategies when needed. Depending on the compound properties, we may combine reverse-phase preparation, normal-phase purification, precipitation, or crystallization exploration to improve process feasibility and sample quality.

What analytical support is needed for PROTAC production?

PROTAC production requires integrated analytical support for structure confirmation, reaction monitoring, impurity profiling, and batch consistency evaluation. HPLC is commonly used to assess main peak content and related components, while LC-MS or HRMS confirms molecular weight and key intermediates. NMR supports structural verification, and additional studies may evaluate solvent residues, water content, stability behavior, and solubility characteristics. For PROTAC compounds intended for in vitro degradation studies, BOC Sciences can also provide project-specific analytical data packages to help clients determine whether the produced material is suitable for screening, mechanism studies, or structure-activity relationship research.

Testimonials

Client Testimonials on PROTAC Scale-Up Production

Route Optimization That Solved a Bottleneck

"Our discovery route was not suitable for gram-scale preparation. BOC Sciences redesigned the key coupling sequence and gave us a process that was much easier to reproduce across batches."

— Senior Scientist at a US-Based Biotechnology Company

Strong Support for Difficult Purification

"The team understood the purification behavior of our highly polar PROTAC and developed a practical isolation workflow. The final material quality was consistent with our research requirements."

— Principal Investigator at a European Pharmaceutical Group

Transparent Technical Communication

"BOC Sciences provided clear reaction data, impurity observations, and scale-up recommendations at each stage. Their communication helped our chemistry team make decisions quickly."

— Director of Medicinal Chemistry at an Oncology Research Company

Reliable Material Supply for Assay Expansion

"We needed larger quantities of a VHL-based degrader for repeat in vitro studies. BOC Sciences delivered comparable batches and helped us move the program forward with confidence."

— Project Manager at a Targeted Protein Degradation Startup